ICG-136

N/A

Report date: 2022/03/31 17:22:56

Base Information

Drug NameICG-136
Drug Alias NameCD123-CD33cCAR T-cellsICG-136123b-33bcCAR
ClassificationCell and gene therapy > Gene therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionC-Type lectin domain family 12 member A modulatorsMyeloid cell surface antigen CD33 modulators
TargetsMyeloid cell surface antigen CD33C-Type lectin domain family 12 member A
Therapy Area/IndicationsLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesIcell Gene Therapeutics (Int'L) Ltd
China Registration ClassN/A

Develop Information

Active CompaniesIcell Gene Therapeutics (Int'L) LtdChengdu Military General Hospital
Inactive CompaniesN/A
Active IndicationsLeukemia, Myeloid, Acute
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A